Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer. The company’s portfolio includes several lines of proprietary chimeric antigen receptor T-cells targeting individual cancers. Its lead product candidate is UCART19, an engineered T-cell product candidate for the treatment of CD19 expressing hematologic malignancies that developed in acute lymphoblastic leukemia and chronic lymphocytic leukemia. The company’s products also include UCART123 for acute myeloid leukemia indications, and UCART38 and UCARTCS1 for multiple myeloma indications.

Homology Medicines, Inc. is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Homology’s proprietary platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a particular focus on rare diseases and a robust intellectual property portfolio with issued composition of matter patents in the United States for its suite of 15 AAVHSCs. Homology believes that its compelling preclinical data, scientific expertise, product development strategy, manufacturing capabilities and intellectual property position it as a leader in the development of genetic medicines.

At the beginning of the twentieth century, tuberculosis was one of the UK’s most urgent health problems. A royal commission, entitled The Royal Commission Appointed to Inquire into the Relations of Human and Animal Tuberculosis, was set up in 1901. It aimed to find out whether tuberculosis in animals and humans was the same disease and whether animals and humans could infect each other. This page describes how, by 1919, the Commission had evolved into the independent Medical Research Council.

Somatogen, Inc. develops specialty oxygen therapeutics. It is engaged in the research, clinical development and commercialization of genetically engineered recombinant human hemoglobin-based products. The company is located in Boulder, CO.

Cornell provides education about the earth and atmospheric sciences. They offer summer and winter sessions. Their students contact them through phone and email services.

Celltrion Inc is a Korea-based company principally engaged in the research, development, and manufacture of therapeutic proteins. The company mainly manufactures biosimilar products, which are used to treat breast cancer, rheumatoid arthritis disease, Crohn's disease, Hodgkin's lymphoma, colorectal cancer, rheumatoid arthritis, respiratory syncytial virus, colon cancer, and others.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Manufactures chemicals

Guangdong Huamei Zhongyuan Biotechnology Co., Ltd., established on 2013-07-25, Business scope includes general items:Biochemical product technology research and development;Engineering and Technology Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Chemical product sales(No licensed chemical products);Medical Research and Experimental Development;Machinery and Equipment Leasing;Cosmetics Retail;Cosmetics Wholesale;Development of Human Gene Diagnosis and Therapy Technology;Sales of Class I Medical Devices;Experimental analysis instrument sales;Drug testing equipment sales;Sales of formula food for special medical purposes;Healthy food(prepackaged)Sales;food sales(Only sell prepackaged food);Food Internet Sales(Only sell prepackaged food);internet sales(Except for products that require a license for sale);Health Consulting Services(Does not include medical services);Environmental Protection Monitoring.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Inspection and testing service;Forensic identification service;medical service;Labor dispatch service;pharmaceutical production;Production of formula food for special medical purpose.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Yaneng Biotechnology produces a gene diagnostic chip technology platform. They provide cervical cancer screening and hereditary disease diagnostics, such as pre pregnancy and prenatal diagnosis and screening tests, and automatic nucleic acid extractor.  They also provide resarch and development services.

Tianjin Biochip Technology Co., Ltd., established on 2003-09-26, The scope of business includes the development of biotechnology products,Production,processing,Sales and related technology transfer;Bioinformatics and Biotechnology Consulting,Serve.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Guangzhou Institutes of Biomedicine and Health (GIBH)，(simplified Chinese: 中国科学院广州生物医药与健康研究院; traditional Chinese: 中國科學院廣州生物醫藥與健康研究院; pinyin: Zhōngguó Kēxué yuan guangzhou sheng wu yi yao yu jian kang yan jiu yuan) affiliated with the Chinese Academy of Sciences, is a government-sponsored scientific research institution with independent legal jurisdiction. GIBH was established by the Chinese Academy of Sciences, Guangdong Provincial Government and Guangzhou Municipal Government. The managerial mechanism of GIBH is the responsibility of Director-General, under the authority of the board of trustees.

Chaozhou Kaipu Biochemical Co., Ltd., established on 2004-04-28, Business scope includes licensed projects:Production of Class III Medical Devices;Production of Class II Medical Devices;Class III medical device business.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are approved by relevant departments,documents or permits shall prevail)General project:Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Manufacturing of special equipment for teaching;Teaching equipment sales;Medical equipment rental;Machinery and Equipment Leasing;Computer and communication equipment rental;Storage equipment rental service;Office equipment rental service;electrical equipment repair;General Equipment Repair;Special Equipment Repair;Computer and Office Equipment Repair;Sales of new energy vehicles;Auto New Car Sales;car used car sales;tram sales;Container Leasing Service;container maintenance;container sales;Sales of electric accessories for new energy vehicles.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Guangzhou Pu Shi Lihua Technology Co., Ltd., established on 2017-07-13, Business scope includes sales of Class I medical devices;Sales of Class II Medical Devices;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Biochemical product technology research and development;Fermentation process optimization technology research and development;R&D of industrial enzyme preparations;Instrument sales;sales agent;Domestic trade agent;trade broker;Class III medical device business;Technology Import and Export;Import and export;Import and export agency;Internet Information Service for Medical Devices;medical service

DIGITAL GRAPHICS, Inc. engages in the production and sale of inkjet printer and printable electronic equipment. It operates through the following business divisions: Textile and Printer, Advertising Printer, Cutting Plotter, Parts, and Rental. The company was founded by Kwan-Soo Choi on January 1, 1985 and is headquartered in Yangju-si, South Korea.

Guangdong Hybribio Biotech Co., Ltd. engages in the research, development, production, and sale of nucleic acid molecular diagnostic products in China. It also provides on-site technical training and after-sales technical service support. The company was founded by Qiao Zhong Guan on June 13, 2003 and is headquartered in Chaozhou, China.

Shenzhen Zhenxing Medical Technology Co., Ltd., established on 2014-03-10, Business scope includes general business items:medical technology,chemical technology,Research and development of biotechnology,consult(Does not contain human stem cells,Development and application of genetic diagnosis and treatment technology,Rare and unique precious fine varieties in China,crop,Breeding livestock,Restricted and prohibited items such as selection and breeding of genetically modified aquatic products,Involving license management and other special regulation management,Operate only after obtaining a license).,The licensing program is:

Shenzhen Zhongke Shenyan Biotechnology Co., Ltd., established on 2012-11-01, Business scope includes general business items:Medical Research and Experimental Development;Biotechnology R&D,Technical Services for Biotechnology,Technology Transfer and Technology Consulting(No restrictions on foreign investment,Prohibited category directory);new drug,Development of pharmaceutical intermediates;Drug related information consultation service;Laboratory equipment,R & D and sales of laboratory consumables;computer software,Information system software and database development and technical services;Operating import and export business(Excluding import distribution,National exclusive control of goods).(above laws,Administrative regulations,Except for items prohibited by the State Council,Restricted projects must obtain a license before operating),The licensing program is:Laboratory equipment,Production of laboratory consumables.

MIBR is developing treatments and vaccines for rare diseases, autoimmune diseases, infectious diseases, cancers, etc. novel drug development using artificial intelligence pursuing the goals of developing new drugs and improving public health on a global scale